Corneal Abrasion and a Request for Hydrocodone
Dr. Okafor sees a 29-year-old woman with a corneal abrasion after a foreign body injury. The abrasion is 4 mm and central. She rates the pain 8/10 and asks for the same hydrocodone-acetaminophen tablets she received from an urgent care clinic last year. Dr. Okafor has a Minnesota optometry license but no DEA registration and has never prescribed a controlled substance. The patient says her primary care clinic cannot see her for five days. She is otherwise healthy, has no signs of infection, and her eye is appropriately treated with a bandage contact lens and topical antibiotic. Dr. Okafor considers writing the hydrocodone prescription to help her through the weekend.
1. Can Dr. Okafor prescribe hydrocodone in this situation? Explain the licensing and scope issues.
Read the worked answer
No. Even if Minnesota law and Board rules permit some optometric prescribing, a licensee must have the required DEA registration to prescribe a controlled substance. Dr. Okafor has none, so writing the hydrocodone prescription would be unlawful regardless of clinical sympathy. Dr. Okafor should also confirm whether the specific controlled substance is within optometric prescribing authority at all; if it is not, that is an independent bar. The correct plan is to optimize topical and noncontrolled analgesia within scope, document the pain assessment, and refer the patient to urgent care or her primary care clinician for controlled pain management. The reasoning is that licensure and registration are separate gates; good intentions do not create prescribing authority.
2. What role, if any, should the prescription monitoring program and documentation play here?
Read the worked answer
Dr. Okafor should not prescribe the controlled substance, but the request still warrants documentation. He should record the patient's report of prior hydrocodone use, the absence of a current prescription, and the referral for pain management. If he is authorized to access the prescription monitoring program and it is relevant to a prescribing decision, he should check it and document the result; a prescriber should not rely only on a patient's recollection. He should also avoid promising that another clinician will prescribe a specific drug. The reasoning is that PMP review supports safe prescribing when a licensee has authority, but it cannot cure the absence of DEA registration or expand scope.